Abstract:diabetes-related symptoms or complications. The subsequent management pathway is subject to national and local guidance. There is no universal audit of this pathway, although various observations can be made through a patchy network of clinical databases, local and national. In addition, some information can beinferredfromreturnstotheQualityandOutcomesFramework through which practices receive some payment for diabetes. Nevertheless, given that the main provision of diabetes care resides in primary care, insights into the management of those individuals managed in that sector are surprisingly thin. As part of a rolling audit on outcomes following referral to a consultant-led diabetes service, we monitor different variables to assess the outcome of the referral. However, as part of that audit, we also monitor baseline glycaemic control and microvascular complications of those referred. We report these results as they may inform the debate around the issue of when subjects with diabetes should be referred for a second opinion. All referrals to a consultant-led community clinic between January and June 2009 were collected. This period was chosen to allow time to form an assessment of the outcome of the referral. Baseline characteristics of referred patients were also collected and it is these results we report here (Table 1). The results shown here indicate that onward referral to a specialist service occurs relatively late in the disease pathway of this group of people. Commonly, it becomes apparent that glycaemic control has been poor for many years when the record is fully examined and, as shown, early complications are apparent. An improvement in the HbA1c value of 10.6 mmol ⁄ mol (0.96%) was readily achieved, with an average of 8.4 months follow-up [although, in those already on insulin where the insulin dose or type was adjusted, the HbA1c fall was only 6.0 mmol ⁄ mol (0.56%)]. Is this too little too late? Current thinking on the management of Type 2 diabetes focuses strongly on macrovascular outcomes. It has become clear that any benefit in this area is achieved only after many years of improved glycaemic control [1]. However, the contribution of glycaemic improvement alone, as opposed to blood pressure and lipid lowering, is relatively small [2]. Furthermore, while improvement in microvascular outcomes should not be overlooked [3], improvements in those with established diabetes may not be quite so striking [4,5]. Nevertheless, there is a clear reduction in mortality, with better glycaemic control down to an HbA1c level of 58.5 mmol ⁄ mol (7.5%) [6]. In that context, is it right that referral for escalation of glycaemic therapy in a UK practice should be such a late occurrence, given that glycaemic improvements seem readily achievable ? While clearly a complex debate, it would appear that the pragmatists in primary care have already cast their vote.

HbA1c in the diagnosis of diabetes: which cut‐off point?

Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms

Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non–Small Cell Lung Cancer

The Progress of PD-1 Inhibitors in Small-Cell Lung Cancer

Combination Immune Checkpoint Inhibitors with Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: What's Known and What's Next.

PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions

The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‐1 antibody suppresses the progression of non‐small cell lung cancer tumors by enhancing immunocompetence

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

IN VIVO ANTIMALARIAL ACTIVITY OF ORAL BETA- ARTEETHER AND PIPERAQUINE COMBINATION.

Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer

Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Research Advances in Mechanism of Antiangiogenic Therapy Combined with Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer

Map arrangement of the SLA chromosomal region and the J and C blood group loci in the pig.

Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy

[Docetaxel in neoadjuvant therapy of early-stage non-small cell carcinoma].

Anlotinib enhanced CD8 + T cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation